Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q2 2020 Earnings Conference Call - Final Transcript
Jul 30, 2020 • 04:30 pm ET
So who knows exactly where we'll be. But if you look at Europe and the way that the pandemic is being managed and frankly, the encouraging rate that the cases are going down, one would think we'll be able to launch in that situation without a great deal of impact from COVID. Certainly, I'm optimistic that will be the case. And so I don't think there'll be any major change to what we're currently planning in terms of what we expect to see from an uptake standpoint in Europe.
And Paul, I'd maybe add one thing to that, and that is that Europe we talk about as a single entity, but it's actually 32 separate countries. And each of those countries have slightly different ways of practicing medicine and slightly different ways of reimbursing and slightly different ways of thinking about patient flowing through their systems. And so we have to look at them individually. And we have market research in all of the key markets that tell us how best to think about a go-to-market strategy in those markets, and there's a nuance in all of them. Obviously, our initial attention and focus is on Germany. And so that's where we spent a lot of time working.
And the sort of second really important thing for us to get right at the end of this year and the beginning of next year is the quality of the submission that we put in for reimbursement of OITs in the other markets.
Thank you. And our next question comes from the line of Derek Archila with Stifel. Your line is open. Please go ahead.
Hi, guys. Thanks for taking my questions, and congrats on the progress. Just two questions. I guess, first off, you kind of gave us a bit of information in terms of how you recognize revenue. And I guess typically, how should we be thinking about the stocking assumption? And obviously, with COVID-19, are practices more reluctant to stock this product until they get more visibility? Or how is that going?
And then a second question for Eric. You talk about being able to fund the company through its current business plan. Does that include profitability? And I guess as we think about the second half spend, should it kind of mirror what we just saw here in the second quarter?
So let me take the first piece, and then Eric can add a bit more flavor to it and answer your second question. So just a point of clarification there. PALFORZIA is not a buy-and-bill product. So the practices themselves do not tend to stock any of this at all. The only thing that we ship to the practices directly is the initial dosing kit, which is the dosing up-titration that they use on the very first day, and then the office dosing kit, which is the box of all the individual starting doses, right? So the bulk of the supply is shipped directly to the patients.